2025-04-08 18:23:59
Latest Post
Godrej Properties delivers its highest ever quarterly and full year bookings
Poonawalla Fincorp Launches Shopkeeper Loan Business
Revolt Motors Expands to 200 Dealerships, Targets 400 by FY26
Sobha Ltd - Real Estate Operational Update - Q4 FY 2024-25
Lemon Tree Hotels signs a new property in DarjeelingStock Report
Marksans Pharma Ltd Q4FY21 consolidated PAT jumps to Rs. 79.49 crore
Posted On : 2021-05-31 13:01:05( TIMEZONE : IST )
MARKSANS PHARMA LTD. has reported financial results for the period ended March 31, 2021.
Financial Results (Q4 FY20-21) - QoQ Comparison
The company has reported total income of Rs.336.21 crores during the period ended March 31, 2021 as compared to Rs.355.19 crores during the period ended December 31, 2020.
The company has posted net profit / (loss) of Rs.79.49 crores for the period ended March 31, 2021 as against net profit / (loss) of Rs.58.94 crores for the period ended December 31, 2020.
The company has reported EPS of Rs.1.93 for the period ended March 31, 2021 as compared to Rs.1.42 for the period ended December 31, 2020.
| Financials | Q4 FY20-21 | Q3 FY20-21 | % Change |
| Total Income | ₹ 336.21 crs | ₹ 355.19 crs |  -5.34% |
| Net Profit | ₹ 79.49 crs | ₹ 58.94 crs |  34.87% |
| EPS | ₹ 1.93 | ₹ 1.42 | 35.92% |
Financial Results (Q4 FY20-21) - YoY Comparison
The company has reported total income of Rs.336.21 crores during the period ended March 31, 2021 as compared to Rs.335.37 crores during the period ended March 31, 2020.
The company has posted net profit / (loss) of Rs.79.49 crores for the period ended March 31, 2021 as against net profit / (loss) of Rs.42.74 crores for the period ended March 31, 2020.
The company has reported EPS of Rs.1.93 for the period ended March 31, 2021 as compared to Rs.1 for the period ended March 31, 2020.
| Financials | Q4 FY20-21 | Q4 FY19-20 | % Change |
| Total Income | ₹ 336.21 crs | ₹ 335.37 crs | 0.25% |
| Net Profit | ₹ 79.49 crs | ₹ 42.74 crs | 85.99% |
| EPS | ₹ 1.93 | ₹ 1 | 93% |
Financial Results (Year ended FY 20-21) - YoY Comparison
The company has reported total income of Rs.1382.87 crores during the 12 months period ended March 31, 2021 as compared to Rs.1134.53 crores during the 12 months period ended March 31, 2020.
The company has posted net profit / (loss) of Rs.238.53 crores for the 12 months period ended March 31, 2021 as against net profit / (loss) of Rs.120.75 crores for the 12 months period ended March 31, 2020.
The company has reported EPS of Rs.5.76 for the 12 months period ended March 31, 2021 as compared to Rs.2.86 for the 12 months period ended March 31, 2020.
| Financials | Year Ended FY20-21 | Year Ended FY19-20 | % Change |
| Total Income | ₹ 1382.87 crs | ₹ 1134.53 crs | 21.89% |
| Net Profit | ₹ 238.53 crs | ₹ 120.75 crs | 97.54% |
| EPS | ₹ 5.76 | ₹2.86 | 101.4% |
Commenting on the performance Mark Saldanha, Managing Director of the Company said "I am pleased to share that our all-round growth of 21.3% in FY21 was on the back of increasing wallet share with existing customers, addition of new logos and new product launches. Our investments in the US business is bearing fruit with EBITDA margin expansion to 24.7% brought about by operating leverage as well as an optimised product mix. We will continue to invest in our businesses to make ourselves future ready while remaining cautiously optimistic of continuing the growth traction in coming quarters."
Shares of MARKSANS PHARMA LTD. was last trading in BSE at Rs.73.95 as compared to the previous close of Rs. 75. The total number of shares traded during the day was 579045 in over 3113 trades.
The stock hit an intraday high of Rs. 76.5 and intraday low of 73.5. The net turnover during the day was Rs. 43502369.
